Bayer AG's AskBio Advances Gene Therapy for Late-Onset Pompe Disease with FDA Approval

Bayer AG Advances Gene Therapy Efforts with FDA Acceptance for Pompe Disease Treatment

Bayer AG's wholly owned subsidiary, AskBio Inc., marks a pivotal moment in gene therapy development with the recent acceptance of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) for AB-1009. This innovative adeno-associated virus (AAV) gene therapy targets late-onset Pompe disease, a rare and serious lysosomal storage disorder. The FDA's endorsement enables AskBio to initiate Phase 1/2 clinical trials, with plans to recruit the first patient as early as 2026. This significant regulatory milestone not only reinforces Bayer's commitment to advancing gene therapies but also highlights the potential for groundbreaking treatments in rare diseases that have long been underserved.

Late-onset Pompe disease, characterized by a deficiency of the enzyme acid alpha-glucosidase (GAA), leads to the harmful accumulation of glycogen in the body’s cells, primarily affecting skeletal muscle. Patients often experience severe muscle weakness and respiratory complications, which can drastically affect quality of life. With an estimated global prevalence of 5,000 to 10,000 individuals, the urgency for effective therapies is evident. The acceptance of the IND for AB-1009 signifies a step forward in addressing this critical healthcare need, providing hope for patients and their families who are facing the debilitating effects of the disease.

The collaboration between AskBio and Belief BioMed (BBM), established in September 2024, further bolsters the development of AB-1009. BBM's grant of a sublicense for its proprietary AAV capsid and vector production services enhances AskBio's capabilities to innovate and streamline the therapeutic process. Dr. Xiao Xiao, Co-founder and Chief Science Officer of BBM, expresses optimism about the collaboration, emphasizing the strong synergy between the two entities. Together, they aim to accelerate the development of this promising gene therapy, ultimately striving to bring relief to those afflicted by late-onset Pompe disease.

In addition to the advancements in gene therapy, Bayer AG's commitment to research and innovation in rare diseases illustrates its broader strategy to address unmet medical needs. The successful IND application for AB-1009 not only showcases Bayer's dedication to scientific excellence but also positions the company at the forefront of pioneering treatments that could redefine patient care in the realm of genetic disorders.

As the clinical trials for AB-1009 approach, industry experts and stakeholders closely monitor the progress, anticipating that this initiative could lead to significant breakthroughs in the treatment of late-onset Pompe disease. The collaborative efforts of AskBio and BBM set a promising precedent for future gene therapy developments, potentially transforming the landscape of treatment options for rare genetic conditions.